trending Market Intelligence /marketintelligence/en/news-insights/trending/bGKMcql_uvnw1Qc4IguX3w2 content esgSubNav
In This List

US FDA grants breakthrough therapy designation to Juno's lymphoma drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA grants breakthrough therapy designation to Juno's lymphoma drug

The U.S. FDA granted Juno Therapeutics Inc. and partner Celgene Corp.'s investigational drug JCAR017 a breakthrough therapy designation for the treatment of patients with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and certain other lymphomas.

The European Medicines Agency's Committee for Medicinal Products for Human Use and Committee for Advanced Therapies granted JCAR017 access to the priority medicines scheme for relapsed/refractory diffuse large B-cell lymphoma. A study is expected to begin in 2017.

The drug is currently not approved in any country.